Utah Medical Products (UTMD)
(Delayed Data from NSDQ)
$69.39 USD
+1.47 (2.16%)
Updated May 6, 2024 04:00 PM ET
After-Market: $69.70 +0.31 (0.45%) 6:30 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
UTMD 69.39 +1.47(2.16%)
Will UTMD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for UTMD based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for UTMD
Utah Medical Products GAAP EPS of $1.09, revenue of $11.34M
UTMD Stock Earnings: Utah Medical Products Reported Results for Q1 2024
Utah Medical: Q1 Earnings Snapshot
Utah Medical Products reports Q1 EPS $1.09 vs. $1.16 last year
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2024